losartan has been researched along with Chronic Kidney Diseases in 60 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 9.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 9.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| " Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria." | 9.16 | Losartan and enalapril are comparable in reducing proteinuria in children. ( Gleim, GW; Lam, C; Massaad, R; Santoro, EP; Shahinfar, S; Sisk, CM; Webb, NJ; Wells, TG, 2012) |
| "Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats." | 8.12 | Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 5.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 5.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 5.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "Baseline estimated GFR (eGFR) and change in eGFR during follow-up were examined in relation to average on-treatment SBP in 8778 hypertensive patients with ECG left ventricular hypertrophy (LVH) randomly assigned to losartan- or atenolol-based treatment." | 5.22 | Impact of achieved systolic blood pressure on renal function in hypertensive patients. ( Devereux, RB; Kjeldsen, SE; Okin, PM, 2016) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "To evaluate the clinical efficacy of syndrome differentiation-based treatment with traditional Chinese medicine (TCM) versus losartan therapy in addition to basic treatment for management of proteinuria in patients with chronic kidney disease." | 5.17 | [Syndrome differentiation-based treatment with traditional Chinese medicine for proteinuria in patients with chronic kidney disease: a randomized multicenter trial]. ( Bi, Y; He, L; Mi, X; Peng, W; Wang, D; Wang, Y; Wu, T; Xie, T; Yuan, M, 2013) |
| " Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria." | 5.16 | Losartan and enalapril are comparable in reducing proteinuria in children. ( Gleim, GW; Lam, C; Massaad, R; Santoro, EP; Shahinfar, S; Sisk, CM; Webb, NJ; Wells, TG, 2012) |
| "Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough." | 4.89 | Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2013) |
| " THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add-on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis." | 4.31 | Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. ( Khazaali, M; Khazaeli, M; Lau, WL; Nunes, ACF; Prudente, J; Singh, B; Vaziri, ND; Zhao, Y, 2023) |
| "Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats." | 4.12 | Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| " Five patients showed clear adverse reactions, with abdominal or gastrointestinal discomfort." | 3.01 | [Efficacy, safety, and mechanism of Huangkui Capsules in treating chronic kidney disease: Meta-analysis and integrative bioinformatics]. ( Liu, Y; Lyu, J; Wang, FP; Xie, YM; Zhang, L, 2023) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| " The incidence of adverse reactions was not different among the 3 groups (P>0." | 2.79 | Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. ( Chang, M; Chen, X; Ding, XQ; Fu, P; Guan, GJ; Hao, L; He, LQ; He, YN; Hu, Z; Li, P; Lin, HL; Lin, S; Liu, ZS; Mei, CL; Miao, LN; Wang, JQ; Wang, L; Wang, R; Wu, XF; Xie, RJ; Xing, CY; Yin, AP; Yuan, FH; Zhang, AP; Zhang, L; Zhang, M; Zhao, JY; Zhou, CH, 2014) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| " Patients received open-label treatment with a conventional dosage of benazepril (10 mg/d), individual uptitration of benazepril (median 20 mg/d; range 10 to 40), a conventional dosage of losartan (50 mg/d), or individual uptitration of losartan (median 100 mg/d; range 50 to 200)." | 2.73 | Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. ( Chen, PY; Guo, ZJ; Hou, FF; Jiang, JP; Liang, M; Xie, D; Zhang, WR; Zhang, X, 2007) |
| "Gout is increasing worldwide." | 2.49 | Hypertension, its treatment, hyperuricaemia and gout. ( Gibson, TJ, 2013) |
| "Idiopathic membranous nephropathy is the main cause of chronic kidney disease (CKD)." | 1.72 | Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy. ( Li, J; Lin, Y; Liu, H; Lv, X; Ma, G; Shao, X; Wang, J; Yu, P; Zhang, L; Zhou, S, 2022) |
| " The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs." | 1.43 | Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. ( Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016) |
| " Both single treatments significantly improved systemic and kidney antioxidant defense, bioavailability of renal nitric oxide, reduced kMMP-1 protein expression and renal injury, thus retarded CKD progression." | 1.43 | Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. ( Grujic-Milanovic, J; Ivanov, M; Jovovic, D; Karanovic, D; Markovic-Lipkovski, J; Mihailovic-Stanojevic, N; Miloradovic, Z; Vajic, UJ; Zivotic, M, 2016) |
| "Enalapril was found to be more reno-protective compared to losartan." | 1.40 | COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL. ( Mugendi, GA; Mwangi, M; Ndwiga, S; Nyamu, DG; Nyamweya, NN; Okalebo, FA, 2014) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 1.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Losartan acts as an immunomodulator that prevents the development of CD14+CD16+ pro-inflammatory monocytes in HD patients." | 1.38 | Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. ( Aljama, P; Alvarez-Lara, MA; Carracedo, J; Martin-Malo, A; Merino, A; Ramirez, R, 2012) |
| "Losartan treatment increased urine and tissue ACE activity and tissue levels of angiotensins, mainly angiotensin (1-7), and improved renal and histopathologic parameters." | 1.38 | Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats. ( Aragão, DS; Arita, DY; Arita, LS; Casarini, DE; Colucci, JA; Cunha, TS; Nogueira, MD; Perez, JD; Ronchi, FA; Teixeira, Vde P, 2012) |
| " Doses were adjusted to equipotent inhibition of the renin-angiotensin system, determined via a dose-response quantifying plasma and renal renin expression." | 1.38 | AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. ( Baucke, J; Danser, AH; Divac, N; Fraune, C; Frenay, AR; Garrelds, IM; Hölzel, A; Jankowski, V; Krebs, C; Lange, S; Nguyen, G; Schwedhelm, E; Stahl, R; Streichert, T; van Goor, H; Velden, J; Wenzel, UO, 2012) |
| "Losartan was administered at a dose of 50 mg/d." | 1.33 | Effect of losartan on slowing progression of chronic allograft nephropathy. ( Fan, MQ; Fang, ZQ; Feng, JY; Huang, CB; Wang, PX; Xiao, Y; Zhang, YP, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (11.67) | 29.6817 |
| 2010's | 39 (65.00) | 24.3611 |
| 2020's | 14 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kovács, ZZA | 1 |
| Szűcs, G | 1 |
| Freiwan, M | 1 |
| Kovács, MG | 1 |
| Márványkövi, FM | 1 |
| Dinh, H | 1 |
| Siska, A | 1 |
| Farkas, K | 1 |
| Kovács, F | 1 |
| Kriston, A | 1 |
| Horváth, P | 1 |
| Kővári, B | 1 |
| Cserni, BG | 1 |
| Cserni, G | 1 |
| Földesi, I | 1 |
| Csont, T | 1 |
| Sárközy, M | 1 |
| van Thiel, BS | 1 |
| van der Linden, J | 1 |
| Ridwan, Y | 1 |
| Garrelds, IM | 3 |
| Vermeij, M | 1 |
| Clahsen-van Groningen, MC | 2 |
| Qadri, F | 1 |
| Alenina, N | 1 |
| Bader, M | 1 |
| Roks, AJM | 1 |
| Danser, AHJ | 2 |
| Essers, J | 1 |
| van der Pluijm, I | 1 |
| Mårup, FH | 1 |
| Peters, CD | 1 |
| Christensen, JH | 1 |
| Birn, H | 1 |
| Askaripour, M | 1 |
| Najafipour, H | 1 |
| Saberi, S | 1 |
| Jafari, E | 1 |
| Rajabi, S | 1 |
| Yoo, TH | 2 |
| Hong, SJ | 1 |
| Kim, S | 1 |
| Shin, S | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Han, SY | 1 |
| Lee, S | 1 |
| Won, JC | 1 |
| Kang, YS | 1 |
| Park, J | 1 |
| Han, BG | 1 |
| Na, KR | 1 |
| Hur, KY | 1 |
| Kim, YJ | 2 |
| Park, S | 2 |
| Lv, X | 1 |
| Wang, J | 1 |
| Zhang, L | 3 |
| Shao, X | 1 |
| Lin, Y | 1 |
| Liu, H | 1 |
| Ma, G | 1 |
| Li, J | 2 |
| Zhou, S | 1 |
| Yu, P | 1 |
| Khazaeli, M | 1 |
| Nunes, ACF | 1 |
| Zhao, Y | 1 |
| Khazaali, M | 1 |
| Prudente, J | 1 |
| Vaziri, ND | 1 |
| Singh, B | 1 |
| Lau, WL | 1 |
| Liu, B | 1 |
| Jie, X | 1 |
| Deng, J | 1 |
| Zhang, S | 1 |
| Lu, F | 1 |
| Liu, X | 1 |
| Zhang, D | 1 |
| Santos, ISR | 1 |
| Martin-Pastor, M | 1 |
| Tavares Júnior, AG | 1 |
| Queiroz, KA | 1 |
| da Silva Sólon, LG | 1 |
| Sousa, FFO | 1 |
| Cooper, TE | 1 |
| Teng, C | 1 |
| Tunnicliffe, DJ | 1 |
| Cashmore, BA | 1 |
| Strippoli, GF | 1 |
| Wang, FP | 1 |
| Lyu, J | 1 |
| Liu, Y | 1 |
| Xie, YM | 1 |
| Bovée, DM | 1 |
| Ren, L | 1 |
| Uijl, E | 1 |
| van Veghel, R | 1 |
| Domenig, O | 1 |
| Poglitsch, M | 1 |
| Zlatev, I | 1 |
| Kim, JB | 1 |
| Huang, S | 1 |
| Melton, L | 1 |
| Lu, X | 1 |
| Hoorn, EJ | 1 |
| Foster, D | 1 |
| Hashimoto, T | 1 |
| Shibata, K | 1 |
| Honda, K | 1 |
| Nobe, K | 1 |
| Ragab, TIM | 1 |
| Ali, NA | 1 |
| El Gendy, ANG | 1 |
| Mohamed, SH | 1 |
| Shalby, AB | 1 |
| Farrag, AH | 1 |
| Shalaby, ASG | 1 |
| Fujihara, CK | 3 |
| Kowala, MC | 1 |
| Breyer, MD | 1 |
| Sena, CR | 1 |
| Rodrigues, MV | 1 |
| Arias, SCA | 1 |
| Fanelli, C | 3 |
| Malheiros, DM | 3 |
| Jadhav, PK | 1 |
| Montrose-Rafizadeh, C | 1 |
| Krieger, JE | 1 |
| Zatz, R | 3 |
| García Trejo, EMÁ | 1 |
| Arellano Buendía, AS | 1 |
| Sánchez Reyes, O | 1 |
| García Arroyo, FE | 1 |
| Arguello García, R | 1 |
| Loredo Mendoza, ML | 1 |
| Tapia, E | 1 |
| Sánchez Lozada, LG | 1 |
| Osorio Alonso, H | 1 |
| Kim, JY | 1 |
| Son, JW | 1 |
| Ryu, DR | 1 |
| Chin, HJ | 1 |
| Montes-Rivera, JO | 1 |
| Tamay-Cach, F | 1 |
| Quintana-Pérez, JC | 1 |
| Guevara-Salazar, JA | 1 |
| Trujillo-Ferrara, JG | 1 |
| Del Valle-Mondragón, L | 1 |
| Arellano-Mendoza, MG | 1 |
| Okin, PM | 1 |
| Kjeldsen, SE | 1 |
| Devereux, RB | 1 |
| Alvarez, M | 1 |
| Ardiles, L | 1 |
| Arias, SC | 1 |
| Valente, CP | 1 |
| Machado, FG | 2 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Jian, DY | 1 |
| Chao, YW | 1 |
| Ting, CH | 1 |
| Huang, SW | 1 |
| Chang, CF | 1 |
| Juan, CC | 1 |
| Chen, JY | 1 |
| Wang, D | 1 |
| Wu, T | 1 |
| Xie, T | 1 |
| Peng, W | 2 |
| Wang, Y | 2 |
| Yuan, M | 1 |
| Mi, X | 1 |
| Bi, Y | 1 |
| He, L | 1 |
| Palkovits, M | 1 |
| Šebeková, K | 1 |
| Klenovics, KS | 1 |
| Kebis, A | 1 |
| Fazeli, G | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Xu, C | 1 |
| Ding, W | 1 |
| Zhang, M | 2 |
| Gu, Y | 1 |
| Li, P | 1 |
| Xing, CY | 1 |
| Zhao, JY | 1 |
| He, YN | 1 |
| Wang, JQ | 1 |
| Wu, XF | 1 |
| Liu, ZS | 1 |
| Zhang, AP | 1 |
| Lin, HL | 1 |
| Ding, XQ | 2 |
| Yin, AP | 1 |
| Yuan, FH | 1 |
| Fu, P | 1 |
| Hao, L | 1 |
| Miao, LN | 1 |
| Xie, RJ | 1 |
| Wang, R | 1 |
| Zhou, CH | 1 |
| Guan, GJ | 1 |
| Hu, Z | 1 |
| Lin, S | 1 |
| Chang, M | 1 |
| He, LQ | 3 |
| Mei, CL | 1 |
| Wang, L | 1 |
| Chen, X | 1 |
| Woo, KT | 1 |
| Choong, HL | 1 |
| Wong, KS | 1 |
| Tan, HK | 1 |
| Foo, M | 1 |
| Fook-Chong, S | 1 |
| Lee, EJ | 1 |
| Anantharaman, V | 1 |
| Lee, GS | 1 |
| Chan, CM | 1 |
| Fujisaki, K | 1 |
| Tsuruya, K | 1 |
| Nakano, T | 1 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 1 |
| Nakayama, M | 1 |
| Hirakata, H | 1 |
| Kitazono, T | 1 |
| Hayashi, M | 1 |
| Uchida, S | 2 |
| Kawamura, T | 1 |
| Kuwahara, M | 1 |
| Nangaku, M | 1 |
| Iino, Y | 1 |
| Yao, Y | 1 |
| Hildreth, CM | 1 |
| Farnham, MM | 1 |
| Saha, M | 1 |
| Sun, QJ | 1 |
| Pilowsky, PM | 1 |
| Phillips, JK | 1 |
| Wu, F | 1 |
| Zhang, PQ | 1 |
| Wang, XQ | 1 |
| Nie, LF | 1 |
| Fu, XJ | 1 |
| Bi, YP | 1 |
| Mi, XH | 1 |
| Gong, XZ | 1 |
| Zhou, LF | 1 |
| Wang, Q | 1 |
| Tang, XC | 1 |
| Qian, YR | 1 |
| Wang, YR | 1 |
| Lu, L | 1 |
| Zhou, JJ | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 1 |
| Gansevoort, RT | 1 |
| Mo, L | 1 |
| Xiao, X | 1 |
| Song, S | 1 |
| Miao, H | 1 |
| Liu, S | 1 |
| Guo, D | 1 |
| Li, X | 1 |
| Bu, C | 1 |
| Hou, L | 1 |
| Yang, X | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Mehrotra, P | 1 |
| Patel, JB | 1 |
| Ivancic, CM | 1 |
| Collett, JA | 1 |
| Basile, DP | 1 |
| Rodríguez-Romo, R | 1 |
| Benítez, K | 1 |
| Barrera-Chimal, J | 1 |
| Pérez-Villalva, R | 1 |
| Gómez, A | 1 |
| Aguilar-León, D | 1 |
| Rangel-Santiago, JF | 1 |
| Huerta, S | 1 |
| Gamba, G | 1 |
| Uribe, N | 1 |
| Bobadilla, NA | 1 |
| Hsing, SC | 1 |
| Lu, KC | 1 |
| Sun, CA | 1 |
| Chien, WC | 1 |
| Chung, CH | 1 |
| Kao, SY | 1 |
| Mugendi, GA | 1 |
| Nyamu, DG | 1 |
| Okalebo, FA | 1 |
| Nyamweya, NN | 1 |
| Ndwiga, S | 1 |
| Mwangi, M | 1 |
| Anan, HH | 1 |
| Zidan, RA | 1 |
| Shaheen, MA | 1 |
| Abd-El Fattah, EA | 1 |
| Koya, Y | 1 |
| Machi, Y | 1 |
| Shobu, Y | 1 |
| Namiki, N | 1 |
| Kotegawa, T | 1 |
| Karanovic, D | 1 |
| Grujic-Milanovic, J | 1 |
| Miloradovic, Z | 1 |
| Ivanov, M | 1 |
| Jovovic, D | 1 |
| Vajic, UJ | 1 |
| Zivotic, M | 1 |
| Markovic-Lipkovski, J | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Guo, LL | 1 |
| Pan, Y | 1 |
| Jin, HM | 1 |
| Kondo, S | 1 |
| Urushihara, M | 1 |
| Kagami, S | 1 |
| Merino, A | 1 |
| Alvarez-Lara, MA | 1 |
| Ramirez, R | 1 |
| Carracedo, J | 1 |
| Martin-Malo, A | 1 |
| Aljama, P | 1 |
| Arita, DY | 1 |
| Cunha, TS | 1 |
| Perez, JD | 1 |
| Colucci, JA | 1 |
| Ronchi, FA | 1 |
| Nogueira, MD | 1 |
| Arita, LS | 1 |
| Aragão, DS | 1 |
| Teixeira, Vde P | 1 |
| Casarini, DE | 1 |
| Vaněčková, I | 1 |
| Kujal, P | 1 |
| Husková, Z | 1 |
| Vaňourková, Z | 1 |
| Vernerová, Z | 1 |
| Certíková Chábová, V | 1 |
| Skaroupková, P | 1 |
| Kramer, HJ | 1 |
| Tesař, V | 1 |
| Červenka, L | 1 |
| Webb, NJ | 1 |
| Shahinfar, S | 1 |
| Wells, TG | 1 |
| Massaad, R | 1 |
| Gleim, GW | 1 |
| Santoro, EP | 1 |
| Sisk, CM | 1 |
| Lam, C | 1 |
| Fraune, C | 1 |
| Lange, S | 1 |
| Krebs, C | 1 |
| Hölzel, A | 1 |
| Baucke, J | 1 |
| Divac, N | 1 |
| Schwedhelm, E | 1 |
| Streichert, T | 1 |
| Velden, J | 1 |
| Danser, AH | 1 |
| Frenay, AR | 1 |
| van Goor, H | 1 |
| Jankowski, V | 1 |
| Stahl, R | 1 |
| Nguyen, G | 1 |
| Wenzel, UO | 1 |
| Shen, PC | 1 |
| Yang, XJ | 1 |
| Cao, HX | 1 |
| Suzuki, H | 2 |
| Shimada, Y | 1 |
| Fujiwara, K | 1 |
| Gibson, TJ | 1 |
| Wang, PX | 1 |
| Fan, MQ | 1 |
| Huang, CB | 1 |
| Feng, JY | 1 |
| Xiao, Y | 1 |
| Fang, ZQ | 1 |
| Zhang, YP | 1 |
| Deng, W | 1 |
| Ding, HG | 1 |
| Chen, J | 1 |
| Yamamoto, T | 1 |
| Nakagawa, T | 1 |
| Ohashi, N | 1 |
| Fukasawa, H | 1 |
| Fujigaki, Y | 1 |
| Kato, A | 1 |
| Nakamura, Y | 1 |
| Suzuki, F | 1 |
| Hishida, A | 1 |
| Hou, FF | 1 |
| Xie, D | 1 |
| Zhang, X | 1 |
| Chen, PY | 1 |
| Zhang, WR | 1 |
| Liang, M | 1 |
| Guo, ZJ | 1 |
| Jiang, JP | 1 |
| Chiang, WC | 1 |
| Lin, SL | 1 |
| Chen, YM | 1 |
| Wu, KD | 1 |
| Tsai, TJ | 1 |
| Poppi, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02620306] | Phase 3 | 351 participants (Actual) | Interventional | 2016-02-11 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial[NCT02231125] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study[NCT02231138] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension[NCT00568178] | Phase 3 | 306 participants (Actual) | Interventional | 2007-06-01 | Completed | ||
| Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy[NCT01300273] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-02-28 | Active, not recruiting | ||
| Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers[NCT00857844] | 207 participants (Actual) | Observational | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -3.8 |
| Amlodipine-Hypertensive Participants | 0.8 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -5.5 |
| Amlodipine-Hypertensive Participants | -0.1 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately twelve weeks of treatment.~Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period." (NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan | -35.80 |
| Amlodipine/Placebo | 1.37 |
"The outcome measure of glomerular filtration rate was based on mL/min/1.73m^2, as determined by the Schwartz formula:~GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL)~GFR values were compared to the baseline GFR measure.~[Note: For male participants, ages 13 to 17 years, 0.70 was used as~the multiplier in place of 0.55]~Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Change in GFR mL/min1.73m^2 (Least Squares Mean) |
|---|---|
| Losartan Open Label Extension | 3.3 |
| Enalapril Open Label Extension | 7.0 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately three years of treatment.~*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan Open Label Extension | -30.01 |
| Enalapril Open Label Extension | -40.45 |
5 reviews available for losartan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2023 |
[Efficacy, safety, and mechanism of Huangkui Capsules in treating chronic kidney disease: Meta-analysis and integrative bioinformatics].
Topics: Capsules; Drugs, Chinese Herbal; Humans; Inflammation; Losartan; Renal Insufficiency, Chronic | 2023 |
Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom | 2013 |
[Progress of pediatric nephrology].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antibodies, Monoclonal, Murine-Derived; Bio | 2011 |
Hypertension, its treatment, hyperuricaemia and gout.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemi | 2013 |
18 trials available for losartan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Hum | 2022 |
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2022 |
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials, Phase III | 2017 |
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Fil | 2016 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
[Syndrome differentiation-based treatment with traditional Chinese medicine for proteinuria in patients with chronic kidney disease: a randomized multicenter trial].
Topics: Adult; Aged; Drugs, Chinese Herbal; Female; Humans; Losartan; Male; Medicine, Chinese Traditional; M | 2013 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Aliskiren and losartan trial in non-diabetic chronic kidney disease.
Topics: Amides; Blood Pressure; Comorbidity; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2014 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2015 |
[Multi-center randomized control study on the effects of syndrome differentiated traditional Chinese medicine therapy on CKD 1-2 with chronic nephritis proteinuria].
Topics: Cell Differentiation; Drugs, Chinese Herbal; Glomerular Filtration Rate; Glomerulonephritis; Humans; | 2015 |
[Effect of Chuanhuang No. 1 recipe on renal function and micro-inflammation in phase 3 chronic kidney disease patients].
Topics: Adult; Blood Urea Nitrogen; C-Reactive Protein; Drugs, Chinese Herbal; Female; Humans; Inflammation; | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Losartan and enalapril are comparable in reducing proteinuria in children.
Topics: Adolescent; Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2012 |
Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Blood Pressure; China; Female; Glomerular Fil | 2012 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2007 |
37 other studies available for losartan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Antihypertensive Agents; Cardiomyopathie | 2021 |
In Vivo Renin Activity Imaging in the Kidney of Progeroid
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA | 2021 |
Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions.
Topics: Aged; Animals; Antioxidants; Female; Fibrosis; Humans; Inflammation; Isoflavones; Kidney; Losartan; | 2022 |
Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy.
Topics: Animals; Autophagy; Canagliflozin; Glomerulonephritis, Membranous; Losartan; Podocytes; Rats; Renal | 2022 |
Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury.
Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules.
Topics: Animals; Fatty Acids; Fibrosis; Humans; Kidney; Losartan; Rats; Renal Insufficiency, Chronic | 2023 |
Metabolomic Profile and Its Correlation with the Plasmatic Levels of Losartan, EXP3174 and Blood Pressure Control in Hypertensive and Chronic Kidney Disease Patients.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Losartan; Renal Insufficiency, Chroni | 2023 |
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Arterial Pressure; Captopril; Dis | 2021 |
Acetic acid treatment causes renal inflammation and chronic kidney disease in mice.
Topics: Acetic Acid; Animals; Creatine; Disease Models, Animal; Gene Expression; Interleukin-1beta; Kidney; | 2021 |
Renoprotective and therapeutic effects of newly water, ethanol, and butanol ginseng fractions in hypertensive and chronic kidney disease with L-NAME.
Topics: Animals; Butanols; Disease Models, Animal; Ethanol; Female; Gas Chromatography-Mass Spectrometry; Ge | 2021 |
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor | 2017 |
The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan.
Topics: Acetylglucosaminidase; Animals; Antihypertensive Agents; Antioxidants; Creatinine; Disulfides; Kelch | 2017 |
Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease.
Topics: Acetophenones; Adjuvants, Pharmaceutic; Animals; Antihypertensive Agents; Antioxidants; Blood Pressu | 2018 |
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D | 2019 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats.
Topics: Adipokines; Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ce | 2013 |
Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Brain; Central Nervous Sy | 2013 |
Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease.
Topics: Angiopoietins; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Dise | 2013 |
The effect of losartan on differential reflex control of sympathetic nerve activity in chronic kidney disease.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Pathways; Baroreflex; Ki | 2015 |
Protective effect of Huang Gan formula in 5/6 nephrectomized rats by depressing the Wnt/β-catenin signaling pathway.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Kidney Fun | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultur | 2015 |
AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Drug Evaluation, Preclinical; | 2016 |
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2015 |
COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL.
Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Diabetic Nephropathies; Enalapril; Female; Humans; | 2014 |
Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; Disease Progression | 2016 |
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions | 2016 |
Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy.
Topics: Animals; Antihypertensive Agents; Antioxidants; Cyclic N-Oxides; Drug Therapy, Combination; Female; | 2016 |
Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients.
Topics: Antihypertensive Agents; Case-Control Studies; Cell Differentiation; Cells, Cultured; Female; Flow C | 2012 |
Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats.
Topics: Animals; Disease Models, Animal; Losartan; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Renal I | 2012 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasent | 2012 |
AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressur | 2012 |
Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Effect of losartan on slowing progression of chronic allograft nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Creatinine; Disease Progression; F | 2005 |
[Treatment of chronic renal insufficiency with losartan and traditional Chinese drug for invigorating spleen and kidney].
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Kidney; Losartan; Medicine, Chinese Traditional; Re | 2006 |
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chemokine CCL2; Cytokines; Female; Follow-Up St | 2008 |
AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Female; Hypertension, Rena | 2008 |